In vitro anti-inflammatory effects of vitamin D supplementation may be blurred in hemodialysis patients

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.

This study aimed to evaluate the potential anti-inflammatory effects of vitamin D supplementation under uremic conditions, both in vivo and in vitro, and its effects on the parameters of mineral metabolism.

Who Took Part

Human monocytes were used for in vitro experiments and treated with cholecalciferol (150 nM) and uremic serum.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the Parathyroid Hormone (PTH 1-84) group a baseline to be compared against.

Serum levels of calcium, phosphate, total alkaline phosphatase, intact parathyroid hormone (iPTH), and vitamin D were measured at baseline and after three and six months.

The levels of fibroblast growth factor-23 (FGF-23), interleukin-1β (IL-1β), and high-sensitivity C-reactive protein (hs-CRP) were also measured at baseline and at six months.

Cell viability, reactive oxygen species (ROS) production, and cathelicidin (CAMP) expression were evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, dichloro-dihydro-fluorescein diacetate assay, and real time-quantitative polymerase chain reaction, respectively.

What Was Measured

PubMed files the paper under topics including Anti-Inflammatory Agents, Cholecalciferol, Dietary Supplements, Fibroblast Growth Factor-23, Parathyroid Hormone, Renal Dialysis and Vitamin D.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Parathyroid Hormone (PTH 1-84).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Clinics (Sao Paulo, Brazil)), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.